<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2024//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_240101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">36670365</PMID><DateCompleted><Year>2023</Year><Month>01</Month><Day>24</Day></DateCompleted><DateRevised><Year>2023</Year><Month>01</Month><Day>24</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">1471-2334</ISSN><JournalIssue CitedMedium="Internet"><Volume>23</Volume><Issue>1</Issue><PubDate><Year>2023</Year><Month>Jan</Month><Day>20</Day></PubDate></JournalIssue><Title>BMC infectious diseases</Title><ISOAbbreviation>BMC Infect Dis</ISOAbbreviation></Journal><ArticleTitle>Hyperbaric oxygen therapy for long COVID (HOT-LoCO), an interim safety report from a randomised controlled trial.</ArticleTitle><Pagination><StartPage>33</StartPage><MedlinePgn>33</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">33</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1186/s12879-023-08002-8</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">With ~ 50 million individuals suffering from post-COVID condition (PCC), low health related quality of life (HRQoL) is a vast problem. Common symptoms of PCC, that persists 3&#xa0;months from the onset of COVID-19 are fatigue, shortness of breath and cognitive dysfunction. No effective treatment options have been widely adopted in clinical practice. Hyperbaric oxygen (HBO<sub>2</sub>) is a candidate drug.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">The objective of this interim analysis is to describe our cohort and evaluate the safety of HBO<sub>2</sub> for post covid condition. In an ongoing randomised, placebo-controlled, double blind, clinical trial, 20 previously healthy subjects with PCC were assigned to HBO<sub>2</sub> or placebo. Primary endpoints are physical domains in RAND-36; Physical functioning (PF) and Role Physical (RP) at 13&#xa0;weeks. Secondary endpoints include objective physical tests. Safety endpoints are occurrence, frequency, and seriousness of Adverse Events (AEs). An independent data safety monitoring board (DSMB) reviewed unblinded data. The trial complies with Good Clinical Practice. Safety endpoints are evaluated descriptively. Comparisons against norm data was done using t-test.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">Twenty subjects were randomised, they had very low HRQoL compared to norm data. Mean (SD) PF 31.75 (19.55) (95% Confidence interval; 22.60-40.90) vs 83.5 (23.9) p&#x2009;&lt;&#x2009;0.001 in Rand-36 PF and mean 0.00 (0.00) in RP. Very low physical performance compared to norm data. 6MWT 442 (180) (95% CI 358-525) vs 662 (18) meters p&#x2009;&lt;&#x2009;0.001. 31 AEs occurred in 60% of subjects. In 20 AEs, there were at least a possible relationship with the study drug, most commonly cough and chest pain/discomfort.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">An (unexpectedly) high frequency of AEs was observed but the DSMB assessed HBO<sub>2</sub> to have a favourable safety profile. Our data may help other researchers in designing trials. Trial Registration ClinicalTrials.gov: NCT04842448. Registered 13 April 2021, https://clinicaltrials.gov/ct2/show/NCT04842448 . EudraCT: 2021-000764-30. Registered 21 May 2021, https://www.clinicaltrialsregister.eu/ctr-search/trial/2021-000764-30/SE.</AbstractText><CopyrightInformation>&#xa9; 2023. The Author(s).</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Kjellberg</LastName><ForeName>Anders</ForeName><Initials>A</Initials><Identifier Source="ORCID">0000-0002-4819-1024</Identifier><AffiliationInfo><Affiliation>Department of Physiology and Pharmacology, Karolinska Institutet, Stockholm, Sweden. anders.kjellberg@ki.se.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Perioperative Medicine and Intensive Care, Medical Unit Intensive Care and Thoracic Surgery, Karolinska University Hospital, Stockholm, Sweden. anders.kjellberg@ki.se.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hassler</LastName><ForeName>Adrian</ForeName><Initials>A</Initials><Identifier Source="ORCID">0000-0002-5796-1801</Identifier><AffiliationInfo><Affiliation>Department of Physiology and Pharmacology, Karolinska Institutet, Stockholm, Sweden.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Medical Unit Emergency Medicine, Karolinska University Hospital, Stockholm, Sweden.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bostr&#xf6;m</LastName><ForeName>Emil</ForeName><Initials>E</Initials><Identifier Source="ORCID">0000-0001-6922-7631</Identifier><AffiliationInfo><Affiliation>Department of Physiology and Pharmacology, Karolinska Institutet, Stockholm, Sweden.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Medical Unit Emergency Medicine, Karolinska University Hospital, Stockholm, Sweden.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>El Gharbi</LastName><ForeName>Sara</ForeName><Initials>S</Initials><Identifier Source="ORCID">0000-0002-0632-1839</Identifier><AffiliationInfo><Affiliation>Department of Physiology and Pharmacology, Karolinska Institutet, Stockholm, Sweden.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Medical Unit Emergency Medicine, Karolinska University Hospital, Stockholm, Sweden.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Al-Ezerjawi</LastName><ForeName>Sarah</ForeName><Initials>S</Initials><Identifier Source="ORCID">0000-0002-5940-6182</Identifier><AffiliationInfo><Affiliation>Department of Physiology and Pharmacology, Karolinska Institutet, Stockholm, Sweden.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Medical Unit Emergency Medicine, Karolinska University Hospital, Stockholm, Sweden.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kowalski</LastName><ForeName>Jan</ForeName><Initials>J</Initials><Identifier Source="ORCID">0000-0001-5414-6556</Identifier><AffiliationInfo><Affiliation>JK Biostatistics AB, Stockholm, Sweden.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rodriguez-Wallberg</LastName><ForeName>Kenny A</ForeName><Initials>KA</Initials><Identifier Source="ORCID">0000-0003-4378-6181</Identifier><AffiliationInfo><Affiliation>Department of Oncology and Pathology, Karolinska Institutet, Stockholm, Sweden.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Division of Gynaecology and Reproduction, Department of Reproductive Medicine, Karolinska University Hospital, Stockholm, Sweden.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bruchfeld</LastName><ForeName>Judith</ForeName><Initials>J</Initials><Identifier Source="ORCID">0000-0001-5399-0982</Identifier><AffiliationInfo><Affiliation>Division of Infectious Diseases, Department of Medicine Solna, Karolinska Institutet, Stockholm, Sweden.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Infectious Diseases, Karolinska University Hospital, Stockholm, Sweden.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>St&#xe5;hlberg</LastName><ForeName>Marcus</ForeName><Initials>M</Initials><Identifier Source="ORCID">0000-0003-0319-6240</Identifier><AffiliationInfo><Affiliation>Department of Medicine Solna, Karolinska Institutet, Stockholm, Sweden.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Medical Unit Cardiology, Heart, Vascular and Neuro Theme, Karolinska University Hospital, Stockholm, Sweden.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Nygren-Bonnier</LastName><ForeName>Malin</ForeName><Initials>M</Initials><Identifier Source="ORCID">0000-0001-6731-8468</Identifier><AffiliationInfo><Affiliation>Division of Physiotherapy, Department of Neurobiology, Care Sciences and Society, Karolinska Institutet, Stockholm, Sweden.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Women's Health and Allied Health Professionals Theme, Medical Unit Occupational Therapy and Physiotherapy, Karolinska University Hospital, Stockholm, Sweden.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Runold</LastName><ForeName>Michael</ForeName><Initials>M</Initials><Identifier Source="ORCID">0000-0001-7568-2278</Identifier><AffiliationInfo><Affiliation>Department of Medicine Solna, Respiratory Medicine Unit, Karolinska Institutet, Stockholm, Sweden.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Respiratory Medicine and Allergy, Karolinska University Hospital, Stockholm, Sweden.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lindholm</LastName><ForeName>Peter</ForeName><Initials>P</Initials><Identifier Source="ORCID">0000-0002-0840-9244</Identifier><AffiliationInfo><Affiliation>Department of Physiology and Pharmacology, Karolinska Institutet, Stockholm, Sweden.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Division of Hyperbaric Medicine, Department of Emergency Medicine, University of California San Diego, La Jolla, CA, 92093, USA.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><DataBankList CompleteYN="Y"><DataBank><DataBankName>ClinicalTrials.gov</DataBankName><AccessionNumberList><AccessionNumber>NCT04842448</AccessionNumber></AccessionNumberList></DataBank></DataBankList><PublicationTypeList><PublicationType UI="D016449">Randomized Controlled Trial</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2023</Year><Month>01</Month><Day>20</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>BMC Infect Dis</MedlineTA><NlmUniqueID>100968551</NlmUniqueID><ISSNLinking>1471-2334</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000086382" MajorTopicYN="Y">COVID-19</DescriptorName><QualifierName UI="Q000628" MajorTopicYN="N">therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000094024" MajorTopicYN="N">Post-Acute COVID-19 Syndrome</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000086402" MajorTopicYN="N">SARS-CoV-2</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006931" MajorTopicYN="Y">Hyperbaric Oxygenation</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011788" MajorTopicYN="N">Quality of Life</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016896" MajorTopicYN="N">Treatment Outcome</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004311" MajorTopicYN="N">Double-Blind Method</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Clinical trial</Keyword><Keyword MajorTopicYN="N">HBOT</Keyword><Keyword MajorTopicYN="N">HRQoL</Keyword><Keyword MajorTopicYN="N">Hyperbaric oxygen</Keyword><Keyword MajorTopicYN="N">Long COVID</Keyword><Keyword MajorTopicYN="N">Post COVID condition</Keyword><Keyword MajorTopicYN="N">RCT</Keyword><Keyword MajorTopicYN="N">Safety</Keyword></KeywordList><CoiStatement>AK and PL disclose funding from Swedish Heart&#x2013;Lung foundation, Stockholm Council and Oura Health Oy for the current trial. MS discloses funding from Swedish Research Council and Dysautonomia International during the trial and previously from HLF. MS also disclose consulting fee from Swedish agency for health technology assessment of social services, speaker honoraria from Orion Pharma, Werfen and has filed a patent for pharmacological treatment in post-COVID POTS. JK disclose consulting fee for statistical work in this trial. AH, EB, SEG, SAE, JK, JB, MNB, MR declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2022</Year><Month>7</Month><Day>12</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2023</Year><Month>1</Month><Day>10</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2023</Year><Month>1</Month><Day>20</Day><Hour>23</Hour><Minute>33</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2023</Year><Month>1</Month><Day>21</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2023</Year><Month>1</Month><Day>25</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2023</Year><Month>1</Month><Day>20</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">36670365</ArticleId><ArticleId IdType="pmc">PMC9854077</ArticleId><ArticleId IdType="doi">10.1186/s12879-023-08002-8</ArticleId><ArticleId IdType="pii">10.1186/s12879-023-08002-8</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Nalbandian A, Sehgal K, Gupta A, Madhavan MV, McGroder C, Stevens JS, et al. Post-acute COVID-19 syndrome. Nat Med. 2021;27(4):601&#x2013;615. doi: 10.1038/s41591-021-01283-z.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41591-021-01283-z</ArticleId><ArticleId IdType="pmc">PMC8893149</ArticleId><ArticleId IdType="pubmed">33753937</ArticleId></ArticleIdList></Reference><Reference><Citation>Soriano JB, Murthy S, Marshall JC, Relan P, Diaz JV. A clinical case definition of post-COVID-19 condition by a Delphi consensus. Lancet Infect Dis. 2021;22:e102&#x2013;e107. doi: 10.1016/S1473-3099(21)00703-9.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1473-3099(21)00703-9</ArticleId><ArticleId IdType="pmc">PMC8691845</ArticleId><ArticleId IdType="pubmed">34951953</ArticleId></ArticleIdList></Reference><Reference><Citation>Shah W, Hillman T, Playford ED, Hishmeh L. Managing the long term effects of covid-19: summary of NICE, SIGN, and RCGP rapid guideline. BMJ. 2021;372:n136. doi: 10.1136/bmj.n136.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/bmj.n136</ArticleId><ArticleId IdType="pubmed">33483331</ArticleId></ArticleIdList></Reference><Reference><Citation>Mehandru S, Merad M. Pathological sequelae of long-haul COVID. Nat Immunol. 2022;23(2):194&#x2013;202. doi: 10.1038/s41590-021-01104-y.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41590-021-01104-y</ArticleId><ArticleId IdType="pmc">PMC9127978</ArticleId><ArticleId IdType="pubmed">35105985</ArticleId></ArticleIdList></Reference><Reference><Citation>Brown K, Yahyouche A, Haroon S, Camaradou J, Turner G. Long COVID and self-management. Lancet. 2022;399(10322):355. doi: 10.1016/S0140-6736(21)02798-7.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0140-6736(21)02798-7</ArticleId><ArticleId IdType="pmc">PMC8776283</ArticleId><ArticleId IdType="pubmed">35065779</ArticleId></ArticleIdList></Reference><Reference><Citation>Efrati S, Golan H, Bechor Y, Faran Y, Daphna-Tekoah S, Sekler G, et al. Hyperbaric oxygen therapy can diminish fibromyalgia syndrome&#x2013;prospective clinical trial. PLoS ONE. 2015;10(5):e0127012. doi: 10.1371/journal.pone.0127012.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0127012</ArticleId><ArticleId IdType="pmc">PMC4444341</ArticleId><ArticleId IdType="pubmed">26010952</ArticleId></ArticleIdList></Reference><Reference><Citation>Akarsu S, Tekin L, Ay H, Carli AB, Tok F, Simsek K, et al. The efficacy of hyperbaric oxygen therapy in the management of chronic fatigue syndrome. Undersea Hyperb Med. 2013;40(2):197&#x2013;200.</Citation><ArticleIdList><ArticleId IdType="pubmed">23682549</ArticleId></ArticleIdList></Reference><Reference><Citation>Bhaiyat AM, Sasson E, Wang Z, Khairy S, Ginzarly M, Qureshi U, et al. Hyperbaric oxygen treatment for long coronavirus disease-19: a case report. J Med Case Rep. 2022;16(1):80. doi: 10.1186/s13256-022-03287-w.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s13256-022-03287-w</ArticleId><ArticleId IdType="pmc">PMC8848789</ArticleId><ArticleId IdType="pubmed">35168680</ArticleId></ArticleIdList></Reference><Reference><Citation>Robbins T, Gonevski M, Clark C, Baitule S, Sharma K, Magar A, et al. Hyperbaric oxygen therapy for the treatment of long COVID: early evaluation of a highly promising intervention. Clin Med (Lond) 2021;21(6):e629&#x2013;e632. doi: 10.7861/clinmed.2021-0462.</Citation><ArticleIdList><ArticleId IdType="doi">10.7861/clinmed.2021-0462</ArticleId><ArticleId IdType="pmc">PMC8806311</ArticleId><ArticleId IdType="pubmed">34862223</ArticleId></ArticleIdList></Reference><Reference><Citation>Kjellberg A, Abdel-Halim L, Hassler A, El Gharbi S, Al-Ezerjawi S, Bostrom E, et al. Hyperbaric oxygen for treatment of long COVID-19 syndrome (HOT-LoCO): protocol for a randomised, placebo-controlled, double-blind, phase II clinical trial. BMJ Open. 2022;12(11):e061870. doi: 10.1136/bmjopen-2022-061870.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/bmjopen-2022-061870</ArticleId><ArticleId IdType="pmc">PMC9638753</ArticleId><ArticleId IdType="pubmed">36323462</ArticleId></ArticleIdList></Reference><Reference><Citation>Zilberman-Itskovich S, Catalogna M, Sasson E, Elman-Shina K, Hadanny A, Lang E, et al. Hyperbaric oxygen therapy improves neurocognitive functions and symptoms of post-COVID condition: randomized controlled trial. Sci Rep. 2022;12(1):11252. doi: 10.1038/s41598-022-15565-0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41598-022-15565-0</ArticleId><ArticleId IdType="pmc">PMC9276805</ArticleId><ArticleId IdType="pubmed">35821512</ArticleId></ArticleIdList></Reference><Reference><Citation>Kjellberg A, De Maio A, Lindholm P. Can hyperbaric oxygen safely serve as an anti-inflammatory treatment for COVID-19? Med Hypotheses. 2020;144:110224. doi: 10.1016/j.mehy.2020.110224.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.mehy.2020.110224</ArticleId><ArticleId IdType="pmc">PMC7456590</ArticleId><ArticleId IdType="pubmed">33254531</ArticleId></ArticleIdList></Reference><Reference><Citation>Hadanny A, Efrati S. The hyperoxic&#x2013;hypoxic paradox. Biomolecules. 2020;10(6):958. doi: 10.3390/biom10060958.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/biom10060958</ArticleId><ArticleId IdType="pmc">PMC7355982</ArticleId><ArticleId IdType="pubmed">32630465</ArticleId></ArticleIdList></Reference><Reference><Citation>FDA. Hyperbaric Oxygen Therapy: Get the Facts: U.S. Food and Drug administration; 2021. https://www.fda.gov/consumers/consumer-updates/hyperbaric-oxygen-therapy-get-facts.</Citation></Reference><Reference><Citation>Schulz KF, Altman DG, Moher D. CONSORT 2010 Statement: updated guidelines for reporting parallel group randomised trials. BMC Med. 2010;8:18. doi: 10.1186/1741-7015-8-18.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/1741-7015-8-18</ArticleId><ArticleId IdType="pmc">PMC2860339</ArticleId><ArticleId IdType="pubmed">20334633</ArticleId></ArticleIdList></Reference><Reference><Citation>Calvert M, Kyte D, Mercieca-Bebber R, Slade A, Chan AW, King MT, et al. Guidelines for inclusion of patient-reported outcomes in Clinical Trial Protocols: the SPIRIT-PRO Extension. JAMA. 2018;319(5):483&#x2013;494. doi: 10.1001/jama.2017.21903.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jama.2017.21903</ArticleId><ArticleId IdType="pubmed">29411037</ArticleId></ArticleIdList></Reference><Reference><Citation>Lansdorp CA, van Hulst RA. Double-blind trials in hyperbaric medicine: a narrative review on past experiences and considerations in designing sham hyperbaric treatment. Clin Trials. 2018;15(5):462&#x2013;476. doi: 10.1177/1740774518776952.</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/1740774518776952</ArticleId><ArticleId IdType="pmc">PMC6136075</ArticleId><ArticleId IdType="pubmed">29865904</ArticleId></ArticleIdList></Reference><Reference><Citation>Tveter AT, Dagfinrud H, Moseng T, Holm I. Health-related physical fitness measures: reference values and reference equations for use in clinical practice. Arch Phys Med Rehabil. 2014;95(7):1366&#x2013;1373. doi: 10.1016/j.apmr.2014.02.016.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.apmr.2014.02.016</ArticleId><ArticleId IdType="pubmed">24607837</ArticleId></ArticleIdList></Reference><Reference><Citation>Ohlsson-Nevo E, Hiyoshi A, Noren P, Moller M, Karlsson J. The Swedish RAND-36: psychometric characteristics and reference data from the Mid-Swed Health Survey. J Patient Rep Outcomes. 2021;5(1):66. doi: 10.1186/s41687-021-00331-z.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s41687-021-00331-z</ArticleId><ArticleId IdType="pmc">PMC8339183</ArticleId><ArticleId IdType="pubmed">34347192</ArticleId></ArticleIdList></Reference><Reference><Citation>Scherbakov N, Szklarski M, Hartwig J, Sotzny F, Lorenz S, Meyer A, et al. Peripheral endothelial dysfunction in myalgic encephalomyelitis/chronic fatigue syndrome. ESC Heart Fail. 2020;7(3):1064&#x2013;1071. doi: 10.1002/ehf2.12633.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/ehf2.12633</ArticleId><ArticleId IdType="pmc">PMC7261521</ArticleId><ArticleId IdType="pubmed">32154656</ArticleId></ArticleIdList></Reference><Reference><Citation>Malik P, Patel K, Pinto C, Jaiswal R, Tirupathi R, Pillai S, et al. Post-acute COVID-19 syndrome (PCS) and health-related quality of life (HRQoL)-a systematic review and meta-analysis. J Med Virol. 2022;94(1):253&#x2013;262. doi: 10.1002/jmv.27309.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/jmv.27309</ArticleId><ArticleId IdType="pmc">PMC8662132</ArticleId><ArticleId IdType="pubmed">34463956</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>